Exact Sciences Corporation

This article is about an American bioscience company. For the branch of sciences, see Exact sciences.
Exact Sciences Corp.
Company typePublic
IndustryMolecular diagnostics
Founded1995 (1995) in Marlborough, Massachusetts
Founders
  • Stanley Lapidus
  • Anthony P. Shuber
HeadquartersMadison, Wisconsin, U.S.
Key people
ProductsCologuard, Oncotype DX, Oncotype MAP
Revenue US$2.50 billion (2023)
US$−215 million (2023)
US$−204 million (2023)
Total assets US$6.47 billion (2023)
Total equity US$3.15 billion (2023)
Number of employees
6,500 (Dec 2023)
Subsidiaries
Subsidiary List
  • Biomatrica
  • Exact Sciences Development
  • Exact Sciences Innovation
  • Exact Sciences International
  • Exact Sciences Laboratories
  • Exact Sciences Thrive
  • Genomic Health
  • Paradigm Diagnostics
  • Prevention Genetics
Websiteexactsciences.com
Footnotes / references

Exact Sciences Corporation is an American molecular diagnostics company based in Madison, Wisconsin, specializing in the detection of early-stage cancers. The company provides products for the detection and prevention of colorectal cancer, including Cologuard, the first stool DNA test for colorectal cancer, along with additional screening and precision oncological tests for other types of cancer.

In November 2025, Abbott Laboratories agreed to acquire Exact Sciences in a deal worth roughly $21 billion.

This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.